10-K/A: Innoviva Inc. Files Amended 10-K to Include Armata Pharmaceuticals' Audited Financials

Innoviva Inc. has filed an amendment to its annual report to include the audited financial statements of Armata Pharmaceuticals, Inc., a company in which it holds a significant stake.

Summary

• Innoviva, Inc. filed an amendment to its 2023 annual report on Form 10-K to include the audited consolidated financial statements of Armata Pharmaceuticals, Inc. for the years ended December 31, 2023 and 2022.
• This amendment was necessary because the financial statements of Armata were not available at the time of the original filing on February 29, 2024, or the first amendment on March 4, 2024.
• The amendment includes the audited balance sheets, statements of operations, statements of cash flow, and statements of stockholders equity for Armata, as well as the consent of Ernst & Young LLP, Armata's independent auditor.
• The document also includes certifications from Innoviva's CEO and CFO, confirming the accuracy of the report.
• The amendment does not change any other information in the original filing, except for the inclusion of Armata's financials.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the going concern issues at Armata, significant losses, and the need for additional capital. The delay in filing the financials also adds to the negative sentiment.

Positives

• The inclusion of Armata's audited financials provides a more complete picture of Innoviva's financial position.
• The filing demonstrates compliance with SEC regulations by including the required financial statements and auditor's consent.
• The certifications from Innoviva's CEO and CFO add credibility to the accuracy of the report.

Negatives

• The need for an amendment suggests that there were delays in obtaining the necessary financial information from Armata.
• Armata's financial statements indicate a history of operating losses and raise concerns about its ability to continue as a going concern.
• Armata's accumulated deficit was $308.8 million as of December 31, 2023.

Risks

• Armata Pharmaceuticals has incurred significant operating losses since its inception and has an accumulated deficit of $308.8 million as of December 31, 2023.
• Armata's ability to continue as a going concern is in doubt, as its existing cash and cash equivalents of $13.5 million as of December 31, 2023, along with a $35 million loan received in March 2024, may not be sufficient to fund operations for the next 12 months.
• Armata's future profitability depends on the successful development, approval, and commercialization of its product candidates, which is not guaranteed.
• Armata may need to raise additional capital through equity offerings, debt financings, or other sources, which may not be available on favorable terms or at all.
• The company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide.

Future Outlook

Armata expects to continue to incur substantial losses and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The company may need to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements.

Management Comments

• The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business.
• Management has determined that it is more likely than not that the Company's net deferred tax assets will not be realized.
• Management believes that there is adequate insurance to cover many different types of liabilities.

Industry Context

This filing is relevant to the biotechnology industry, particularly companies focused on developing novel therapeutics for antibiotic-resistant infections. The inclusion of Armata's financials is important for investors in Innoviva, as Armata is a significant investment for the company. The going concern issues at Armata are not uncommon in the biotech industry, where companies often rely on external funding to support their research and development efforts.

Comparison to Industry Standards

• Armata's financial situation, with significant losses and reliance on external funding, is not uncommon for clinical-stage biotech companies.
• Companies like Entasis Therapeutics (acquired by Innoviva) and La Jolla Pharmaceutical Company (also acquired by Innoviva) have faced similar challenges in their development stages.
• The need for additional capital raises is a common theme among biotech companies, especially those focused on novel therapies like bacteriophages.
• The level of R&D spending at $33.8 million in 2023 is typical for a company in Armata's stage of development, but the lack of revenue generation is a concern.
• The going concern issue is a significant risk factor that is often disclosed by companies in this sector, and Armata's disclosure is consistent with industry standards.

Related Party Transactions

• Innoviva SO, a wholly owned subsidiary of Innoviva Inc., owns 69.4% of Armata's outstanding equity as of December 31, 2023.
• Armata received $90.0 million in total debt financing from Innoviva SO during 2023 and in March 2024.
• Innoviva designees represent three out of eight Board of Directors seats at Armata.

Stakeholder Impact

• Shareholders of Innoviva are impacted by the financial performance of Armata.
• Employees of Armata are impacted by the company's financial stability and ability to continue operations.
• Customers and partners of Armata are impacted by the company's ability to develop and commercialize its products.
• Creditors of Armata are impacted by the company's ability to repay its debts.

Next Steps

• Armata needs to secure additional financing to continue its operations.
• Innoviva will likely monitor Armata's financial performance and progress closely.
• Armata will continue to pursue the development and commercialization of its product candidates.

Key Dates

Keywords

Innoviva, Armata Pharmaceuticals, 10-K/A, Financial Statements, Audited Financials, Amendment, SEC Filing, Going Concern, Bacteriophage, Biotechnology